fingolimod "zentiva" 0,5 mg kapsler, hårde
zentiva k.s. - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
fingolimod "glenmark" 0,5 mg kapsler, hårde
glenmark pharmaceuticals nordic ab - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
fingolimod "krka" 0,5 mg kapsler, hårde
krka d.d. novo mesto - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
gaxenim 0,5 mg kapsler, hårde
bausch health ireland limited - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
fingolimod mylan
mylan ireland limited - fingolimod hydrochlorid - multipel sklerose, recidiverende-remitterende - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1)orpatients med hurtigt udviklende alvorlige relapserende remitterende multipel sklerose, der er defineret ved 2 eller flere invaliderende tilbagefald i et år, og med 1 eller flere gadolinium øge læsioner på hjernen mr-scanning eller en betydelig stigning i t2 læsion belastning i forhold til en tidligere de seneste mr -.
fingolimod mylan
mylan ireland limited - fingolimod hydrochlorid - multipel sklerose, recidiverende-remitterende - immunosuppressiva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 og 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fingolimod "orion" 0,5 mg kapsler, hårde
orion corporation - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
fingolimod "tillomed" 0,5 mg kapsler, hårde
tillomed pharma gmbh - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
inzolfi 0,5 mg kapsler, hårde
sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,5 mg
inzolfi 0,25 mg kapsler, hårde
sandoz a/s - fingolimodhydrochlorid - kapsler, hårde - 0,25 mg